


What is claimed is:

1. A method of treating leukemia, carcinoma, melanoma, and/or sarcoma, comprising administering to a mammal a therapeutically effective amount of a compound represented by the following Formula (I) or salt, hydrate, or solvate thereof:



Formula (I)

wherein:

n represents a number from 3 to 7;


m represents a number from 1 to 2;

R₁ and R₂ independently represent a hydrogen atom or are a substituted or unsubstituted, branched or unbranched or cyclic, alkyl provided that the total number of carbon atoms represented by R₁ and R₂ when taken together is no less than 5; or R₁ and R₂ together independently represent a cyclic alkyl group having no less than 3 or no more than 7 carbon atoms;

R₃ and R₄ independently represent a hydrogen atom or a saturated or unsaturated, substituted or unsubstituted, branched or unbranched or cyclic, hydrocarbonyl radical, or R₃ and R₄ together with the nitrogen represent at least a 4-member heterocyclic group.

2. The method of claim 1 wherein at least one of said R₃ or R₄ includes alkyl.
3. The method of claim 1 wherein R₃ and R₄ independently represent a hydrogen atom or a straight chain alkyl having no less than 1 and no more than 3 carbon atoms; or R₃ and R₄ together with the nitrogen form a 5- to 8-member heterocyclic group.
4. The method of any one of the preceding claims further comprising the administration of a chemotherapeutic or potentiating agent.

5. The method of claim 4, wherein the chemotherapeutic or potentiating agent is selected from triprolidine or its cis-isomer, procodazole, 1H-Benzimidazole carbamate-2-propanoic acid; propazol, monensin, bromodeoxyuridine, dipyridamole, indomethacin, metoclopramide, 7-thia-8-oxoguanosine, N-solanesyl-N,N'-bis(3,4-dimethoxybenzyl)ethylenediamine, leucovorin, heparin, N-[4-[(4-fluorophenyl)sulfonyl]phenyl] acetamide, heparin sulfate, cimetidine, vitamin A, 2'-deoxycoformycin, or dimethyl sulfoxide.
6. The method of any one of the preceding claims wherein the compound is N, N-diethyl-8,8-dipropyl-2-azaspiro[4,5]decane-2-propanamine; or a pharmaceutically acceptable salt, hydrate or solvate thereof.
7. The method of any one of the preceding claims wherein the compound is administered orally.
8. The method of any one of the preceding claims wherein the compound is administered parenterally.
9. The method of any one of the preceding claims wherein from about 0.05 to about 100 mg/kilogram of total body weight of the compound are administered per day.
10. The method of any one of the preceding claims wherein said mammal is a human.
11. A method of treating cancer comprising administering to a mammal a therapeutically effective amount of a N, N-diethyl-8,8-dipropyl-2-azaspiro[4,5] decane-2-propanamine dimaleate.
12. A method of treating cancer comprising administering to a mammal a therapeutically effective amount of a compound represented by the following Formula (I) or salt, hydrate, or solvate thereof:



Formula (I)

wherein:

n represents a number from 3 to 7;


m represents a number from 1 to 2;

R₁ and R₂ independently represent a hydrogen atom or are a substituted or unsubstituted, branched or unbranched or cyclic, alkyl provided that the total number of carbon atoms represented by R₁ and R₂ when taken together is no less than 5; or R₁ and R₂ together independently represent a cyclic alkyl group having no less than 3 or no more than 7 carbon atoms;

R₃ and R₄ independently represent a hydrogen atom or a saturated or unsaturated, substituted or unsubstituted, branched or unbranched or cyclic, hydrocarbyl radical, or R₃ and R₄ together with the nitrogen represent at least a 4-member heterocyclic group;

wherein said cancer includes Hodgkin's Disease, Non-Hodgkin's Lymphoma, neuroblastoma, breast cancer, ovarian cancer, lung cancer, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia, small-cell lung tumors, primary brain tumors, stomach cancer, colon cancer, malignant pancreatic insulanoma, malignant carcinoid, urinary bladder cancer, premalignant skin lesions, testicular cancer, lymphomas, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary tract cancer, malignant hypercalcemia, cervical cancer, endometrial cancer, adrenal cortical cancer, and prostate cancer.

13. A method of suppressing or retarding angiogenesis in a cancer or a tumor, comprising administering to a mammal a therapeutically effective amount of a compound represented by the following Formula (I) or salt, hydrate, or solvate thereof:



Formula (I)

wherein:


n represents a number from 3 to 7;

m represents a number from 1 to 2;

R₁ and R₂ independently represent a hydrogen atom or are a substituted or unsubstituted, branched or unbranched or cyclic, alkyl provided that the total number of carbon atoms represented by R₁ and R₂ when taken together is no less than 5; or R₁ and R₂ together independently represent a cyclic alkyl group having no less than 3 or no more than 7 carbon atoms;

R₃ and R₄ independently represent a hydrogen atom or a saturated or unsaturated, substituted or unsubstituted, branched or unbranched or cyclic, hydrocarbyl radical, or R₃ and R₄ together with the nitrogen represent at least a 4-member heterocyclic group.

14. A method for accelerating the rate of apoptosis in cancer cells comprising treating said cells with a therapeutically effective amount of a compound represented by the following Formula (I) or salt, hydrate, or solvate thereof:



Formula (I)

wherein:

n represents a number from 3 to 7;


m represents a number from 1 to 2;

R₁ and R₂ independently represent a hydrogen atom or are a substituted or unsubstituted, branched or unbranched or cyclic, alkyl provided that the total number

of carbon atoms represented by R_1 and R_2 when taken together is no less than 5; or R_1 and R_2 together independently represent a cyclic alkyl group having no less than 3 or no more than 7 carbon atoms;

R_3 and R_4 independently represent a hydrogen atom or a saturated or unsaturated, substituted or unsubstituted, branched or unbranched or cyclic, hydrocarbyl radical, or R_3 and R_4 together with the nitrogen represent at least a 4-member heterocyclic group.

15. A method of inhibiting the proliferation of cancer cells comprising treating said cells with a therapeutically effective amount of a compound represented by the following Formula (I) or salt, hydrate, or solvate thereof:



Formula (I)

wherein:


n represents a number from 3 to 7;

m represents a number from 1 to 2;

R_1 and R_2 independently represent a hydrogen atom or are a substituted or unsubstituted, branched or unbranched or cyclic, alkyl provided that the total number of carbon atoms represented by R_1 and R_2 when taken together is no less than 5; or R_1 and R_2 together independently represent a cyclic alkyl group having no less than 3 or no more than 7 carbon atoms;

R_3 and R_4 independently represent a hydrogen atom or a saturated or unsaturated, substituted or unsubstituted, branched or unbranched or cyclic, hydrocarbyl radical, or R_3 and R_4 together with the nitrogen represent at least a 4-member heterocyclic group.

16. A method of decreasing the secretion of VEGF in cancer cells comprising treating said cells with a therapeutically effective amount of a compound represented by the following Formula (I) or salt, hydrate, or solvate thereof:



Formula (I)

wherein:


n represents a number from 3 to 7;

m represents a number from 1 to 2;

R₁ and R₂ independently represent a hydrogen atom or are a substituted or unsubstituted, branched or unbranched or cyclic, alkyl provided that the total number of carbon atoms represented by R₁ and R₂ when taken together is no less than 5; or R₁ and R₂ together independently represent a cyclic alkyl group having no less than 3 or no more than 7 carbon atoms;

R₃ and R₄ independently represent a hydrogen atom or a saturated or unsaturated, substituted or unsubstituted, branched or unbranched or cyclic, hydrocarbyl radical, or R₃ and R₄ together with the nitrogen represent at least a 4-member heterocyclic group.

17. A kit for treating cancer comprising administering to a mammal a therapeutically effective amount of a compound represented by the following Formula (I) or salt, hydrate, or solvate thereof:



Formula (I)

wherein:

n represents a number from 3 to 7;

m represents a number from 1 to 2;

R₁ and R₂ independently represent a hydrogen atom or are a substituted or unsubstituted, branched or unbranched or cyclic, alkyl provided that the total number

of carbon atoms represented by R_1 and R_2 when taken together is no less than 5; or R_1 and R_2 together independently represent a cyclic alkyl group having no less than 3 or no more than 7 carbon atoms;

R_3 and R_4 independently represent a hydrogen atom or a saturated or unsaturated, substituted or unsubstituted, branched or unbranched or cyclic, hydrocarbyl radical, or R_3 and R_4 together with the nitrogen represent at least a 4-member heterocyclic group; and instructions on a dosage regimen.

18. The kit of claim 17 wherein the compound is provided in discrete quantities.
19. The kit of claim 17 wherein the kit is designed for administration to humans.
20. The kit of claim 17 wherein the instruction provide notations specific to certain types of cancer.